phenylephrine

Australian Law Firm Sues Johnson & Johnson Over Ineffective Cold Medicine

JGA Saddler, an Australian law firm, launched a class action lawsuit against Johnson & Johnson, alleging the company falsely advertised the effectiveness of phenylephrine in products like Codral and Sudafed. The lawsuit centers on the FDA’s declaration that oral phenylephrine is ineffective as a nasal decongestant, contradicting Johnson & Johnson’s marketing claims. This action followed the replacement of pseudoephedrine with phenylephrine after pseudoephedrine sales restrictions, potentially leaving consumers with ineffective congestion relief. Consumers who purchased these products since 2005 may be eligible for compensation if the lawsuit is successful.

Read More

FDA Proposes Removing Ineffective Cold Medicine Phenylephrine from Market

The Food and Drug Administration has proposed removing oral phenylephrine, a common ingredient in over-the-counter cough and cold medicines, from the market due to its ineffectiveness as a nasal decongestant. This decision follows the agency’s own scientific review, which found that oral phenylephrine is poorly absorbed into the bloodstream and its effectiveness is questionable, contradicting earlier studies. The FDA is seeking public comment on this proposal, and if finalized, manufacturers will need to remove or reformulate products containing oral phenylephrine. While the FDA considers oral phenylephrine safe at current levels, it acknowledges that higher doses would be needed to achieve any meaningful effect, raising safety concerns.

Read More